Homeopathic treatment of ringworm

A Comparative Effectiveness Study of 50 Millesimal Potencies and Centesimal Potencies in the Treatment of Tinea Corporis: An Open, Randomized, Pragmatic Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016065

Enrollment

Registered

2018-10-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Homeopathic individualised medicines in centesimal potencies: Intervention is planned as administering indicated homeopathic medicines in centesimal potencies, as decided appropriate to

dosage and repetition depending upon the individual requirement of the cases. All medicines will be procured from a Good Manufacturing Practice (GMP)-certified firm. Along with the indicated medicine

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosed case of Tinea corporis, suffering for at least 3 months (ICD 10 B35.4) 2. Age 18-65 yrs 3. Both sexes 4. Literate patients who are able to read or write 5. Patient using topical agents for tinea lesions will be included after a washout period of two weeks

Exclusion criteria

Exclusion criteria: 1. Cases with complications like lichenification and eczematisation 2. Similar looking skin conditions; e.g. seborrhic dermatitis, pityriasis rosea and some types of psoriasis 3. Patients who are too sick for consultation, unable to read patient information sheet, unwilling to take part or not giving consent to join the study 4. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure 5. Pregnant women and lactating mothers 6. Substance abuse and/or dependence 7. Self-reported immune-compromised state, and 8. Already undergoing homeopathic treatment for chronic disease within last 6 months

Design outcomes

Primary

Measure	Time frame
0-10 Numeric rating scale measuring intensity of itchingTimepoint: At baseline, after 6 weeks and after 12 weeks	—

Secondary

Measure	Time frame
Dermatological Life Quality Index (DLQI) questionnaireTimepoint: At baseline, after 6 weeks and after 12 weeks;Skindex-29 questionnaireTimepoint: At baseline, after 6 weeks and after 12 weeks	—

Countries

India

Contacts

Public ContactShyamal Kumar Mukherjee

D.N.De Homoeopathic Medical College and Hospital

shyamalmukhergee@gmail.com9831113383

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026